The Assay Development and Diagnostics Section (ADDS) leads in the development, evaluation, and production of molecular assays. It offers routine molecular diagnostics and sequencing services for surveillance, outbreak investigations, and research. The section conducts EREID diagnostics and HIV drug resistance genotyping. Its highly skilled staff are proficient in handling various molecular diagnostic platforms, including nucleic acid detection and sequencing. Additionally, the section has a strong bioinformatics component for data analysis and interpretation. It also spearheads in the conduct of confirmatory testing and formulates the laboratory surge capacity plan.
The Assay Development and Diagnostics Section comprises three teams: the Molecular Assay Development and Production team, the Molecular Testing team, and the Molecular Assay Evaluation Team. By providing and leveraging essential molecular technologies, the section actively supports AMTL's goal of protecting the Philippines from novel, emerging, and re-emerging infectious diseases. This is achieved through conducting research in the adoption of cutting-edge molecular biology tools and the development of locally-produced molecular assays.Â